We partner with the media to inform the public of the global human crisis.
May 25, 2018Indivior Announces Regulatory Submission to Australia’s Therapeutic Goods Administration (TGA) for SUBLOCADE™ (Buprenorphine Extended-Release) Injection for the Treatment of Opioid Dependence...
May 17, 2018Result of AGM...
May 14, 2018Indivior Enters into Settlement with Par Pharmaceutical in Patent Infringement Case...
May 1, 2018Indivior Q1 2018 Results On Track. FY 2018 Guidance Reconfirmed. Encouraging SUBLOCADE™ Launch....
April 20, 2018Indivior Announces New Drug Submission to Health Canada for SUBLOCADE™ (Buprenorphine Extended-Release) Injection for the Treatment of Moderate to Severe Opioid Use Disorder...
Global Media Contacts
The Online Press Kit is designed to help media research our company for background information or follow-up stories. Please visit the links below to learn more.
About Indivior PLC – An overview of Indivior, including our worldwide locations and key products
Board of Directors – Biographies of Indivior’s Board
The Indivior PLC Pipeline – Information about the Indivior R&D efforts and progress of medicines in the pipeline